Gaucher Disease Drugs Market Overview
The Gaucher Disease Drugs Market is estimated to reach $1.7 billion by 2028, growing at a CAGR of 1.9% over the forecast period 2023-2028. The increasing population and increased rate of disease worldwide are anticipated to have a significant impact on the growth of the global Gaucher Disease Drugs Market size. Gaucher disease is a hereditary illness in which fat-filled Gaucher cells accumulate in organs such as the spleen, liver and bone marrow. Low levels of the enzyme glucocerebrosidase or GCase, which breaks down the fatty substance glucocerebroside in the body, are the root cause of Gaucher disease. Gaucher cells are regular macrophage scavenger cells that swell up with unprocessed glucocerebroside. Gaucher disease can be classified as Gaucher disease type 1, Gaucher disease type 2 and Gaucher disease type 3 depending on the severity of the condition. The prevalence of Gaucher disease type 1 is the highest, accounting for more than 90%, while Gaucher disease type 2 and Gaucher disease type 3 are less prevalent, according to National Organization for Rare Disorders (NORD).
Gaucher Disease Drugs Market Report Coverage
The report: “Gaucher Disease Drugs Market – Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Gaucher Disease Drugs Market.
- Geographically, North America dominates the Gaucher Disease Drugs Market in 2022, owing to the advancement of modern medical technology and a well-established healthcare system. Asia-Pacific is the fastest growing region in the market during the forecast period 2023-2028, owing to the high rate of unmet clinical patient requirements.
- The growing demand for a sufficiently effective therapy for the disease is the key factor driving the Gaucher Disease Drugs market.
- The Gaucher Disease Drugs market size would grow as a result of the rising acceptance rate of early diagnosis and the increasing number of government initiatives to raise awareness.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Gaucher Disease Drugs Market Report.
Gaucher Disease Drugs Market Segment Analysis – by Disease Type:
Based on disease type, the Gaucher Disease Drugs Market is further segmented into Gaucher Disease Type 1, Gaucher Disease Type 2 and Gaucher Disease Type 3. Gaucher Disease Type 1 held the largest revenue share of the Gaucher Disease Drugs Market in 2022, as around 95% of patients with Gaucher disease type 1 live in western countries, where it is the most common type of the disease, according to National Gaucher Foundation. Spleen and liver enlargement, bone issues and weariness are among the symptoms. However, Gaucher Disease Type 3 segment is estimated to grow at the fastest CAGR of 2.2% over the forecast period 2023-2028, since it is a common disease type worldwide and causes the same symptoms as type 1, adding some neurological abnormalities and falls between kinds 1 and 2 in severity.
Gaucher Disease Drugs Market Segment Analysis – by Therapy Type:
Based on therapy type, the Gaucher Disease Drugs Market is further segmented into Enzyme Replacement Therapy and Substrate Replacement Therapy. The Enzyme Replacement Therapy (ERT) segment held the largest revenue share of the Gaucher Disease Drugs Market in 2022, as in patients with Gaucher disease, enzyme replacement therapy (ERT) balances low levels of GCase so their bodies can breakdown glucocerebroside. It typically takes 1-2 hours for patients to get ERT via IV infusion. Generally, patients require an ERT injection every 2 weeks. Each environment has advantages for ERT treatment, whether choose to receive it at home, a Gaucher disease treatment facility or an infusion center. However, Substrate Replacement Therapy (SRT) segment is anticipated to grow at the fastest CAGR of 2.4% over the forecast period 2023-2028, as it is a more recent technique that functions differently from ERT. SRT is an oral drug that lowers the body's production of glucocerebroside, preventing excess accumulation.
Gaucher Disease Drugs Market Segment Analysis – by Geography:
Based on Geography, the North American Gaucher Disease Drugs Market accounted for 37% of the revenue share in 2022. This is because of the growing treatment awareness as well as expanding treatment options. The increasing patient population is also anticipated to expand the Gaucher Disease Drugs Market size in the region. According to Global Epidemiology of Gaucher Disease, the birth prevalence of Gaucher Disease in North America is 1.3 cases per 100,000 live births in 2021. However, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period 2023-2028, owing to the growing disease awareness and greater disposable income in the region. According to Global Epidemiology of Gaucher Disease, the birth prevalence of Gaucher Disease in Asia-Pacific is 1.1 cases per 100,000 live births in 2021.
Gaucher Disease Drugs Market Drivers
Innovative Healthcare Infrastructure Attracts Major Market Players:
One of the largest and most developed healthcare markets in the world is found in the United States. According to Gaucher Disease Global Epidemiology, the average life expectancy has increased from 66.8 to 73.4 years, a rise of more than 6 years. Governments all across the world are engaged in global initiatives such as the advancement of medical technology and healthcare infrastructure. Enzyme replacement treatment providers can target this nation to benefit from the sophisticated and well-established healthcare infrastructure, which fosters innovative approaches to drug discovery and fosters a fertile atmosphere for significant medical research advancements. The use of innovative and cutting-edge technology, the existence of well-known ERT providers and increased funding for medical research and development are some other factors influencing the demand for Gaucher disease enzyme replacement therapy.
Growing Population Worldwide:
Gaucher disease patients occasionally have no symptoms and children are more prone to the disorder than older people. Thus, the increasing population around the world is anticipated to have a significant impact on the growth of the global Gaucher Disease Drugs Market size for treating Gaucher disease. According to Global Epidemiology of Gaucher Disease, the prevalence of Gaucher illness is 0.72 to 1.70 per 100,000 individuals worldwide in 2021 and affects both men and women equally. While some people can develop Gaucher disease, others can become carriers of the condition, meaning they can carry the Gaucher gene to their offspring despite not having the disease themselves.
Gaucher Disease Drugs Market Challenge
High Price of Gaucher Disease Treatment:
Gaucher disease requires extensive resources for treatment. Living with Gaucher illness can be expensive. The primary treatment for Gaucher disease, enzyme replacement therapy (ERT), costs between $139,000 to more than $300,000 annually. During their treatment, patients frequently incur unforeseen charges, such as emergency service fees and travel expenses. According to the National Library of Medicine (NLM), the estimated average annual economic cost of Gaucher disease is $48,771. The average direct healthcare expenditures for Gaucher disease are estimated at $41,816.2 (85.7% of total costs) and they were primarily made up of the costs for taking medication at home (61.3%), receiving inpatient care (15.3%), receiving outpatient care (3.8%) and having tests like blood tests and imaging tests done (3.4%). Many Gaucher disease patients struggle to maintain their health while under a heavy financial burden. Gaucher disease patients are capable of leading normal lives, but they need to consistently receive the right care.
Gaucher Disease Drugs Industry Outlook:
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Gaucher Disease Drugs Industry. The top 10 companies in the Gaucher Disease Drugs Industry are:
Key Industry Players:
- AVROBIO, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company, Pfizer Inc.
- PerkinElmer Inc., GlaxoSmithKline plc,
- AstraZeneca PLC
- Sanofi-aventis Groupe
- Takeda Pharmaceutical Company Limited
- Janssen Global Services, LLC.
- In August 2022, Turning Point Therapeutics, Inc. was acquired by Bristol Myers Squibb in an all-cash deal. Turning Point is a fully owned subsidiary of Bristol Myers Squibb after the transaction was finalized.
- In July 2022, AstraZeneca acquired TeneoTwo, Inc. The company includes TNB-486, a CD19/CD3 T-cell engaged in Phase I clinical testing for B-cell non-Hodgkin's lymphoma that has relapsed and become resistant to treatment. This prospective new treatment for B-cell hematologic malignancies, such as diffuse large B-cell lymphoma and follicular lymphoma, is being developed with the purchase of TNB-486.
- In December 2020, Eli Lilly and Company Pvt. Ltd. acquired Prevail Therapeutics in order to start a gene therapy program to treat catastrophic hereditary illnesses.
Report Code: HCR 0334
Report Code: HCR 0961
Report Code: HCR 0051
For more Lifesciences and Healthcare Market reports, please click here